Discovery of a human monoclonal antibody that cross-neutralizes venom phospholipase A2s from three different snake genera
Christoffer V. Sørensen, José R. Almeida, Markus‐Frederik Bohn, Esperanza Rivera‐de‐Torre, Sanne Schoffelen, Björn G. Voldborg, Anne Ljungars, Sakthivel Vaiyapuri, Andreas H. Laustsen
Abstract
Despite the considerable global impact of snakebite envenoming, available treatments remain suboptimal. Here, we report the discovery of a broadly-neutralizing human monoclonal antibody, using a phage display-based cross-panning strategy, capable of reducing the cytotoxic effects of venom phospholipase A2s from three different snake genera from different continents. This highlights the potential of utilizing monoclonal antibodies to develop more effective, safer, and globally accessible polyvalent antivenoms that can be widely used to treat snakebite envenoming.